Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Exercise hormone irisin blocks Parkinson's-associated α-synuclein aggregation and related neuronal toxicity

A new paper discusses the hope held out by recent results on a compound called irisin, a short protein secreted by skeletal muscle that produces some exercise-related effects on the brain.

15 Sep 2022

Exercise hormone reduces protein levels linked to Parkinson's disease

Researchers from Johns Hopkins Medicine and the Dana Farber Cancer Institute in Boston have shown that a hormone secreted into the blood during endurance, or aerobic, exercise reduces levels of a protein linked to Parkinson's disease and halts movement problems in mice.

12 Sep 2022

Updated guidelines on the Valneva SARS-CoV-2 vaccine

The WHO provides interim guidelines for the use of the Valneva vaccine.

23 Aug 2022

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

A new study reviews recent advancements made in the development of RSV immunoprophylactic measures.

11 Aug 2022

Hybrid immunity retained six months after SARS-CoV-2 exposure

Scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as the reduced severity of Omicron infections.

3 Aug 2022

Gene therapy approach delays disease onset in humanized mouse models of familial ALS

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord responsible for voluntary movements and muscle control.

2 Aug 2022

Moderna COVID vaccine is more effective in older and sicker veterans over time

Researchers report the higher effectiveness of the Moderna COVID-19 vaccine as compared to the Pfizer COVID-19 vaccine.

28 Jul 2022

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

A new study discusses the development of recombinant vesicular stomatitis virus COVID-19 vaccines.

25 Jul 2022

Why Omicron is more infectious than other SARS-CoV-2 variants

Researchers describe SARS-CoV-2 Omicron mutations and their impact on neutralization and infectivity.

25 Jul 2022

SARS-CoV-2 spike protein can lead to heart muscle injury through the inflammatory process

Heart damage is common among patients hospitalized with COVID-19, leading many to wonder how the virus affects the heart.

25 Jul 2022

The durability of immunity and the likelihood of breakthrough infections following vaccination with four well-studied COVID-19 vaccines

Researchers compared the durability of vaccine-induced immunity and natural infection against COVID-19.

20 Jul 2022

Gut-lung axis: Using commensal bacteria to reinforce mucosal immunity

A recent study discusses the use of commensal bacteria in the gut and/or respiratory tract to deliver viral antigens to the host, thus acting as vaccines

19 Jul 2022

Healthy, cancer, and immunosuppressed patients all benefit from COVID boosters

In a recent study posted to the medRxiv* pre-print server, researchers developed a mechanistic mathematical model to predict the course of vaccine-induced immunity in healthy and immunosuppressed patients for the long term, exceeding the time frames for which clinical data is currently available.

5 Jul 2022

Model predicts effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants

In a recent study published in the journal Nature Medicine, researchers assessed the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against symptomatic infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs) by genetic mismatch/distance (GD) analysis.

20 Jun 2022

People with HIV are at greater risk of breakthrough COVID-19 infections after vaccination

People with HIV have a higher rate of breakthrough COVID-19 infections after vaccination, compared to people without HIV, according to findings from a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

7 Jun 2022

Safety and efficacy of SCB-2019 COVID vaccine candidate as a ChAdOx1-S booster

In a recent study posted to the medRxiv* pre-print server, researchers evaluated the immunogenicity of booster doses of alum-adjuvanted SCB-2019 vaccine candidate's three formulations.

6 Jun 2022

Gene therapy for degenerative retinal disease has no safety concerns but fails to improve vision loss

A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries visual signals from the light-sensing retina to the brain.

1 Jun 2022

Viral Vector News and Research

Further Reading

Exercise hormone irisin blocks Parkinson's-associated α-synuclein aggregation and related neuronal toxicity

Exercise hormone reduces protein levels linked to Parkinson's disease

Updated guidelines on the Valneva SARS-CoV-2 vaccine

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

Hybrid immunity retained six months after SARS-CoV-2 exposure

Gene therapy approach delays disease onset in humanized mouse models of familial ALS

Moderna COVID vaccine is more effective in older and sicker veterans over time

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

Why Omicron is more infectious than other SARS-CoV-2 variants

SARS-CoV-2 spike protein can lead to heart muscle injury through the inflammatory process

The durability of immunity and the likelihood of breakthrough infections following vaccination with four well-studied COVID-19 vaccines

Gut-lung axis: Using commensal bacteria to reinforce mucosal immunity

Healthy, cancer, and immunosuppressed patients all benefit from COVID boosters

Model predicts effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants

People with HIV are at greater risk of breakthrough COVID-19 infections after vaccination

Safety and efficacy of SCB-2019 COVID vaccine candidate as a ChAdOx1-S booster

Gene therapy for degenerative retinal disease has no safety concerns but fails to improve vision loss

Study analyzes how four types of COVID-19 vaccines prepare the body to fight SARS-CoV-2

Direct comparison of immune memory responses to four COVID-19 vaccines

New therapeutic approach harnesses the body's immune system to protect against brain damage

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News